An experimental malaria vaccine developed by GlaxoSmithKline Plc has reduced the risk of malaria by half in African children between the ages of five and 17 months. The results have been published in the New England Journal of Medicine. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy Research & University News
